The Ebola epidemic is threatening not only west Africans’ lives, but also the progress toward democracy, economic growth and social integration that Liberia, Sierra Leone and Guinea have made in the past decade. To protect their achievements, the three countries’ governments, which comprise the Mano River Union, must buttress their response to the epidemic with a coordinated strategy to prevent future outbreaks.
However, they cannot do it alone. Though several experimental treatments and at least two candidate vaccines had been in development when Ebola emerged unexpectedly early this year, progress had stalled well before any were deemed ready to be tested in humans. After all, clinical research to assess the safety and effectiveness of new drugs and vaccines can happen only during an epidemic.
As health workers labor tirelessly to care for those who have been infected, monitor those who may have come in contact with the virus and prevent further transmission, researchers have a limited window of opportunity to learn how to treat and prevent the disease. To accelerate progress, governance of the clinical trials must be transparent and all knowledge about the disease, including developments regarding potential treatments and vaccines, must be shared openly — imperatives that require strong public health leadership in both the Mano River countries and the developed world.
The good news is that some progress is being made, with several vaccine clinical trials already under way. Moreover, with support from the WHO, at least one international platform for clinical trials has been created to assess the safety and efficacy of experimental Ebola treatments, as well as to establish scientific and ethical standards of care.
Unfortunately, these efforts lack adequate involvement by west African researchers, clinicians, health workers and health officials. Running clinical trials under the auspices of affected countries’ health ministries and the WHO — with full transparency in terms of processes and outcomes — would enable the relevant authorities to make timely and informed decisions regarding which treatments and vaccines to investigate further, and when to deploy them.
The fight against infectious diseases like Ebola is one that affects everyone. In order to succeed, we must capitalize on the expertise of those who have been quietly, diligently and independently studying such diseases. They must share with those at the front lines information about diseases’ natural history, modes of transmission and risk factors, as well as preclinical data on — and clinical responses to — experimental treatments.
At the same time, more scientific expertise must be devoted to analyzing the shared data and providing new ideas about prevention and treatment. If researchers are not coming forward on their own, health ministries and organizations must develop strategies to attract them — and fast. As many ideas as possible are needed.
Such an “open source” approach is not standard practice in pharmaceutical research and development. However, the crisis has laid bare the inadequacy of the prevailing approach.
In fact, the Ebola epidemic is not the first public health disaster to highlight the failings of the existing system. Pharmaceutical companies have been reluctant to make the antiretroviral medications used to treat HIV/AIDS available in a cost-effective manner for public health use. With business interests dictating global pharmaceutical priorities, developing countries consistently lose out — with devastating consequences.
In any public health crisis — especially one like the current Ebola outbreak — potential profits cannot guide drug development or deployment. As soon as a vaccine or treatment is deemed suitable for implementation, it must be made available in large quantities, to be administered quickly to citizens at no cost to them.
Of course, transparent clinical trials and open data platforms raise legitimate ethical and intellectual-property concerns. Compassionate drug use (the provision of experimental drugs in urgent circumstances) remains controversial. And, given the high cost of research and development, pharmaceutical companies are naturally concerned about competitors reverse-engineering their drugs.
However, these longstanding concerns should not be allowed to impede efforts to address the immediate threat that Ebola poses. Instead, the crisis should reinvigorate debate about these issues, with the goal of refining the balance between public health and business interests, and thereby improving the global response to future crises.
In the meantime, these concerns underscore the need for public health officials to be involved in monitoring and coordinating clinical trials, and for improved information-sharing among experts and affected countries. An open data platform would facilitate discussion of the social value of clinical research and the associated ethical dilemmas.
Time is of the essence. The world needs a flexible, adaptive, ethical and transparent approach to treatment and prevention that allows for rapid decisionmaking in the development phase and effective coordination in the deployment phase.
The countries affected by the devastating Ebola epidemic will undoubtedly feel its impact for years to come. With strong public health leadership and effective coordination in the fight against infectious disease, people in west Africa — indeed, the entire world — would be able to rest assured that another resurgence of Ebola is not just around the corner.
Abdul Tejan-Cole is executive director of the Open Society Initiative for West Africa.
Copyright: Project Syndicate
Recently, China launched another diplomatic offensive against Taiwan, improperly linking its “one China principle” with UN General Assembly Resolution 2758 to constrain Taiwan’s diplomatic space. After Taiwan’s presidential election on Jan. 13, China persuaded Nauru to sever diplomatic ties with Taiwan. Nauru cited Resolution 2758 in its declaration of the diplomatic break. Subsequently, during the WHO Executive Board meeting that month, Beijing rallied countries including Venezuela, Zimbabwe, Belarus, Egypt, Nicaragua, Sri Lanka, Laos, Russia, Syria and Pakistan to reiterate the “one China principle” in their statements, and assert that “Resolution 2758 has settled the status of Taiwan” to hinder Taiwan’s
Singaporean Prime Minister Lee Hsien Loong’s (李顯龍) decision to step down after 19 years and hand power to his deputy, Lawrence Wong (黃循財), on May 15 was expected — though, perhaps, not so soon. Most political analysts had been eyeing an end-of-year handover, to ensure more time for Wong to study and shadow the role, ahead of general elections that must be called by November next year. Wong — who is currently both deputy prime minister and minister of finance — would need a combination of fresh ideas, wisdom and experience as he writes the nation’s next chapter. The world that
The past few months have seen tremendous strides in India’s journey to develop a vibrant semiconductor and electronics ecosystem. The nation’s established prowess in information technology (IT) has earned it much-needed revenue and prestige across the globe. Now, through the convergence of engineering talent, supportive government policies, an expanding market and technologically adaptive entrepreneurship, India is striving to become part of global electronics and semiconductor supply chains. Indian Prime Minister Narendra Modi’s Vision of “Make in India” and “Design in India” has been the guiding force behind the government’s incentive schemes that span skilling, design, fabrication, assembly, testing and packaging, and
As former president Ma Ying-jeou (馬英九) wrapped up his visit to the People’s Republic of China, he received his share of attention. Certainly, the trip must be seen within the full context of Ma’s life, that is, his eight-year presidency, the Sunflower movement and his failed Economic Cooperation Framework Agreement, as well as his eight years as Taipei mayor with its posturing, accusations of money laundering, and ups and downs. Through all that, basic questions stand out: “What drives Ma? What is his end game?” Having observed and commented on Ma for decades, it is all ironically reminiscent of former US president Harry